Invanz

Ertapenem

Treatment of moderate to severe infections in adult & ped (≥3 mth of age) patients w/ complicated intra-abdominal infections due to E. coli, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus spp, Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, or Bacteroides uniformis; complicated skin & skin structure infections, including diabetic foot infections w/o osteomyelitis due to Staph aureus (methicillin-susceptible isolates only), Strep agalactiae, Strep pyogenes, E. coli, Klebsiella pneumoniae, Proteus mirabilis, Bacteroides fragilis, Peptostreptococcus spp, Porphyromonas asaccharolytica, or Prevotella bivia; community acquired pneumonia due to Strep pneumoniae (penicillin-susceptible isolates only), including cases w/ concurrent bacteremia, H. influenzae (β-lactamase -ve isolates only), or Moraxella catarrhalis; complicated UTI including pyelonephritis due to E. coli, including cases w/ concurrent bacteremia, or Klebsiella pneumoniae; acute pelvic infections including postpartum endomyometritis, septic abortion & post-surgical gynecological infections due to Strep agalactiae, E. coli, Bacteroides fragilis, Porphyromonas asaccharolytica, Peptostreptococcus spp, or Prevotella bivia. Prophylaxis of surgical site infection following elective colorectal surgery in adults.

IV infusion for up to 14 days (infuse over a 30-min period) or IM inj for up to 7 days. Adult & ped patient ≥13 yr 1 g once daily. Ped patient 3 mth-12 yr 15 mg/kg bd, max 1 g/day. Duration of treatment: Complicated intra-abdominal infections 5-14 days. Complicated skin & skin structure infections, including diabetic foot infections w/o osteomyelitis 7-14 days. Community acquired pneumonia &/or complicated UTI, including pyelonephritis 10-14 days. Acute pelvic infections including postpartum endomyometritis, septic abortion & post-surgical gynecologic infections 3-10 days. Adult Prophylaxis of surgical site infection following elective colorectal surgery Single 1 g IV dose given 1 hr prior to surgical incision. Adult w/ severe renal impairment (CrCl ≤30 mL/min/1.73 m²) & ESRD (CrCl ≤10 mL/min/1.73 m²) 500 mg daily. Adult on hemodialysis Supplementary dose of 150 mg is recommended following hemodialysis session when recommended daily dose of 500 mg is given w/in 6 hr prior to hemodialysis.

Hypersensitivity to ertapenem, carbapenem antibiotics, & other β-lactams. Hypersensitivity to lidocaine or amide-type local anesth when administered as IM inj.

History of hypersensitivity to penicillins, cephalosporins, other β-lactams & other allergens. Immediately discontinue if allergic reaction occurs. Caution w/ IM administration to avoid inadvertent inj into a blood vessel. Reports of seizures & other CNS adverse experiences, especially in patients w/ CNS disorders (eg, brain lesions or history of seizures) &/or compromised renal function. Reports of Clostridioides difficile-associated diarrhea. Prolonged use may result in overgrowth of non-susceptible organisms. Increased risk to develop drug-resistant bacteria if prescribed in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication. Periodic assessment of organ system function, including renal, hepatic, & hematopoietic, is advisable during prolonged therapy. Not recommended w/ concomitant use of valproic acid/divalproex Na; probenecid. Patients w/ renal impairment (CrCl ≤30 mL/min). Pregnancy & lactation. Not recommended in infants <3 mth of age. Not recommended in treating meningitis in the ped population. No data in patients undergoing peritoneal dialysis or hemofiltration; ped patients w/ renal impairment &/or on hemodialysis.

As treatment in adults: Diarrhea, infused vein complication, nausea, headache, vaginitis. As treatment in ped patients: Diarrhea, infusion site pain or erythema, vomiting. As prophylaxis of surgical site infection following elective colorectal surgery in adults: Anemia, small intestinal obstruction, pneumonia, post-op infection, UTI, wound infection, wound complication, atelectasis.

Increased plasma conc w/ probenecid. Decreased serum conc of valproic acid.

Other Beta-Lactams

J01DH03 - ertapenem ; Belongs to the class of carbapenems. Used in the systemic treatment of infections.

A